Last updated: May 5, 2022
Sponsor: Shanghai Henlius Biotech
Overall Status: Active - Recruiting
Phase
2
Condition
N/ATreatment
N/AClinical Study ID
NCT04976647
HLX10HLX07-sqNSCLC-201
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Histologically confirmed diagnosis of previously untreated, Recurrent or MetastaticSquamous Non-Small Cell Lung Cancer
- EGFR immunohistochemistry (IHC) H score ≥200 assessed by central lab
- Has measurable disease as defined by RECIST 1.1 as determined by the IRRC
- Has a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG)Performance Scale
- Has a life expectancy of greater than 12 weeks
- Has adequate organ function
Exclusion
Exclusion Criteria:
- Histologically non-squamous NSCLC must be exclused. For non-small-cell histology, ifhas squamous components be allowed
- Has history of such as PD-1/PD-L1、EGFR、 CTLA4 targeted therapy
- EGFR sensitivity mutation or ALK or ROS1 gene rearrangement need to be excluded
- Has had other active malignancies within 5 years or at the same time
- Has uncontrolled pleural effusion、pericardial effusion or ascites
Study Design
Total Participants: 156
Study Start date:
January 18, 2022
Estimated Completion Date:
October 30, 2024
Connect with a study center
Guangdong Provincial People's Hospital
Guangzhou, Guangdong 510080
ChinaActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.